Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
A bill amending the FD&C Act to clarify the regulatory framework with respect to “certain non-prescription drugs that are marketed without an approved new drug application, and for other purposes,” was introduced to Congress. The “Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018” is in the first stage of the legislative process. Statements on the legislation were issued by CHPA and NSF.
[/membership]